HWAM
TBPH icon

Hennion & Walsh Asset Management’s Theravance Biopharma TBPH Stock Holding History

Hennion & Walsh Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-62,546
Closed -$463K – 784
2021
Q3 		$463K Sell
62,546
-2,700
-4% -$30.2K 0.02% 525
2021
Q2 		$947K Sell
65,246
-37,302
-36% -$700K 0.05% 372
2021
Q1 		$2.09M Buy
+102,548
New +$1.95M 0.13% 221

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Hennion & Walsh Asset Management's TBPH Position: Q4 2021 in Review

Hennion & Walsh Asset Management sold out of Theravance Biopharma (TBPH) in Q4 2021, closing a stake of 62,546 shares — an estimated $463K sold.

Hennion & Walsh Asset Management first reported a position in TBPH in Q1 2021 and held it in 3 quarters. The position peaked at $2.09M in Q1 2021. 116 funds tracked by Wall St. Rank hold TBPH as of Q4 2021.

  • Hennion & Walsh Asset Management reported no remaining Theravance Biopharma position as of Q4 2021 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 62,546 Theravance Biopharma shares in Q4 2021, an estimated $463K.
  • Hennion & Walsh Asset Management first reported a position in Theravance Biopharma in Q1 2021 and held it in 3 quarters.
  • Hennion & Walsh Asset Management's Theravance Biopharma position peaked at $2.09M in Q1 2021.
  • 116 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2021.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.